Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Automated immunofluorometric assay for MUC1.

L F Norum1, O Nilsson, K Nustad

  • 1Central Laboratory, Norwegian Radium Hospital, Oslo, Norway.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|March 29, 2001
PubMed
Summary

A new automated immunofluorometric assay (MUC1 IFMA) for the breast cancer marker MUC1 was developed and validated. This reliable assay shows comparable results to commercial tests and will aid in finding optimal MUC1 assays.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activation of EphA receptors on CD4+CD45RO+ memory cells stimulates migration.

Journal of leukocyte biology·2010
Same author

Characterization of monoclonal antibodies directed against squamous cell carcinoma antigens: report of the second TD-10 workshop.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine·2009
Same author

BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.

British journal of cancer·2004
Same author

Characterization of monoclonal antibodies directed against squamous cell carcinoma antigens: report of the TD-10 Workshop.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine·2004
Same author

Tumor marker workshops.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine·2003
Same author

Expulsion of small strongyle nematodes (cyathostomin spp) following deworming of horses on a stud farm in Sweden.

Veterinary parasitology·2003

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • The MUC1 tumor-associated antigen is a significant biomarker in breast cancer diagnostics.
  • Developing robust and automated assays is crucial for reliable MUC1 monitoring.
  • Existing commercial assays for MUC1 present limitations in automation and evaluation capacity.

Purpose of the Study:

  • To establish a robust, reliable, and fully automated immunofluorometric assay for the breast cancer serum marker MUC1 (MUC1 IFMA).
  • To serve as a prototype for evaluating new MUC1 assays based on novel antibody combinations.
  • To compare the performance of the new MUC1 IFMA with existing commercial assays.

Main Methods:

  • Development of an automated immunofluorometric assay (MUC1 IFMA) utilizing time-resolved fluorescence.

Related Experiment Videos

  • Comparison of MUC1 IFMA with two commercial assays: CA15-3 EIA (CanAg) and ETI-CA-15-3 K (Sorin).
  • Evaluation of assay performance metrics including coefficient of variation and diagnostic sensitivity/specificity.

    • Main Results:

    • The MUC1 IFMA demonstrated a coefficient of variation below 10% across a wide concentration range (9–2,400 kU/l).
    • Overall diagnostic sensitivities were comparable across the three assays (MUC1 IFMA: 0.40, CA15-3 EIA: 0.37, ETI-CA-15-3 K: 0.38) at 0.94 specificity.
    • All assays showed high sensitivity (close to 0.80) when applied to metastatic breast cancer samples, with a strong correlation (Spearman rank = 0.99) between MUC1 IFMA and CA15-3 EIA.

    Conclusions:

    • The automated MUC1 IFMA is a reliable and robust assay suitable for clinical application and research.
    • The assay's performance is comparable to established commercial tests, offering improved automation and capacity.
    • The MUC1 IFMA principle provides a valuable platform for the rapid evaluation of new antibody combinations for optimal MUC1 detection.